Current management of locally advanced pancreatic cancer (Q36304248)

13 August 2017

1 reference

title

Current management of locally advanced pancreatic cancer (English)

1 reference

13 August 2017

1 reference

Vivek Maheshwari

1

1 reference

13 August 2017

A James Moser

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Nature Reviews Gastroenterology & Hepatology

13 August 2017

1 reference

13 August 2017

2

1 reference

13 August 2017

8

1 reference

13 August 2017

356-364

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpgasthep0240

13 August 2017

0 references

cites work

Chemotherapy for advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Pancreaticoduodenectomy with vascular resection: margin status and survival duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Treatment of pancreatic cancer: challenge of the facts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Systemic treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Surgical palliation for pancreatic cancer. The UCLA experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Paclitaxel and concurrent radiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Docetaxel and Radiotherapy and Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Carcinoma of the periampullary region: who benefits from portal vein resection?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Pancreaticoduodenectomy with en bloc portal vein resection for pancreatic carcinoma with suspected portal vein involvement

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Survival benefits of portal vein resection for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0240

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0240

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference